Ann: FDA Approves Sofdra, page-211

I've been on heaps of Shares that have done CRs after pivotal announcements, and most of the time, they always go up.

Anyway, if the volume of shares goes from 1.5B to 1.7B, the market cap drops but if the shares go up, it will equal or better.
The long-term strategy looks awesome IMO. If Bot can make earnings of 2% not taking expenses into account, that brings the price to $5.48 with current shares on issue, or $4.87 with the additional 200 mill.

Anyway, even if I've stuffed this up to some degree. I'm pretty sure the long-term strategy is going ot be mega, so if an additional $60 mill is needed, that do it.

	Before CR
1	Current Market Cap	$527,700,000.00
2	Current Share price	0.335
3	Shares on Market	1,575,223,881
4
5	Patients needing treatment	16,000,000
6	Achievable market percentage	2%
7
8	Percentage of customers treated	320,000
9	Cost of goods (COG)	$750.00
10	Months needing treatment	12
11
12	Gross Revenue	$2,880,000,000.00
13	Exp	NFI
14	Shares divided by Revenue	$1.83
15	Growth Potential PE	3
16
17	Current price	$5.48

	After CR
1	Current Market Cap	$527,700,000.00
2	Current Share price	0.30
3	Shares on Market	1,775,223,881
4
5	Patients needing treatment	16,000,000
6	Achievable market percentage	2%
7
8	Percentage of customers treated	320,000
9	Cost of goods (COG)	$750.00
10	Months needing treatment	12
11
12	Gross Revenue	$2,880,000,000.00
13	Exp	NFI
14	Shares divided by Revenue	$1.62
15	Growth Potential PE	3
16
17	Current price * Growth potential	$4.87